Novartis pays $10m milestone to Array BioPharma
The milestone payment was triggered from the first patient enrollment in an open-label Phase 2 study to evaluate the safety and efficacy of MEK162 in patients with malignant
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.